ArticleClinical and experimental immunology2006
Immunomodulation using the recombinant monoclonal human B7-DC cross-linking antibody rHIgM12.
Article in Clinical and experimental immunology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 37 citations in OpenAlex.
- Immunoregulatory functions of VISTA.Immunological reviews · 2017Review
- Frontline Science: Defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1.Journal of leukocyte biology · 2016Observational
- Concomitant Use of Neuroprotective Drugs in Neuro Rehabilitation of Multiple Sclerosis.International journal of physical medicine & rehabilitation · 2016Article
- Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis.Expert opinion on biological therapy · 2016Review
- Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies.Biochimica et biophysica acta · 2016Review
- Need for a paradigm shift in therapeutic approaches to CNS injury.Expert review of neurotherapeutics · 2012Review
- Evidence for the role of B cells and immunoglobulins in the pathogenesis of multiple sclerosis.Neurology research international · 2011Article
- PD-1, gender, and autoimmunity.Autoimmunity reviews · 2010Review
- Octamer binding protein 2 (Oct2) regulates PD-L2 gene expression in B-1 cells through lineage-specific activity of a unique, intronic promoter.Genes and immunity · 2010Article
- Invited article: human natural autoantibodies in the treatment of neurologic disease.Neurology · 2009Review
- CTL activation using the natural low-affinity epitope 222-229 from tyrosinase-related protein 1 leads to tumor rejection.Cancer research · 2009Article
- Indirect recruitment of a CD40 signaling pathway in dendritic cells by B7-DC cross-linking antibody modulates T cell functions.PloS one · 2009Article
- The complex role of B7 molecules in tumor immunology.Trends in molecular medicine · 2008Review
- T-bet expression by dendritic cells is required for the repolarization of allergic airway inflammation.European journal of immunology · 2008Article
- Reprogrammed FoxP3+ T regulatory cells become IL-17+ antigen-specific autoimmune effectors in vitro and in vivo.Journal of immunology (Baltimore, Md. : 1950) · 2008Article
- Dendritic cell programming by cytomegalovirus stunts naive T cell responses via the PD-L1/PD-1 pathway.Journal of immunology (Baltimore, Md. : 1950) · 2008Article
- The programmed death-1 and interleukin-10 pathways play a down-modulatory role in LP-BM5 retrovirus-induced murine immunodeficiency syndrome.Journal of virology · 2008Article
- PD-1 and its ligands in tolerance and immunity.Annual review of immunology · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
A patient with Waldenstrom's macroglobulinaemia expresses a high titre IgM antibody in serum that binds both mouse and human dendritic cells (DC) in a B7-DC (PD-L2)-dependent manner. We have reported previously that purified antibody from patient serum activates immature and mature DC in vitro, enhancing the ability of these professional antigen-presenting cells to activate naive T cells, take up antigen, resist a cytokine-depleted environment and secrete immunomodulatory cytokines, such as interleukin (IL)-6 and tumour necrosis factor (TNF)-alpha. Systemic treatment of experimental animals with this antibody induces potent anti-melanoma immunity and modulates protectively the recall response against antigen challenge through the airway in an experimental model of inflammatory airway disease. Here we describe a monoclonal IgM antibody derived from this serum immunoglobulin that recapitulates each of these earlier observations, providing direct evidence that M protein from the Waldenstrom's patient mediates these potent immunomodulatory effects. Furthermore, cell lines expressing this recombinant form of the human antibody provide the basis for developing this reagent for clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.